BioMarin Stock Jumps After Settling Yuviwel Patent Fight With Ascendis

BioMarin and Ascendis end all Yuviwel patent fights. Ascendis will pay 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030.